

Ref: FOI/GS/ID 6984

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

22 December 2021

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to anti-VEGF treatments for eye conditions.

*You asked:*

*1. For the 4-month period from May to August 2021, how many patients has your trust treated with the following anti-VEGF treatments:*

- a. Aflibercept*
- b. Bevacizumab*
- c. Brolucizumab*
- d. Dexamethasone*
- e. Fluocinolone acetonide*
- f. Ranibizumab*

*2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.*

- a. Aflibercept*
- b. Bevacizumab*
- c. Brolucizumab*
- d. Dexamethasone*
- e. Fluocinolone acetonide*
- f. Ranibizumab*

*3. Within your trust, how many intra-vitreous injections/implants of each following treatments have been used (for any eye condition) in the four-month period from May to August 2021:*

- a. Aflibercept*
- b. Bevacizumab*
- c. Brolucizumab*
- d. Dexamethasone*
- e. Ranibizumab*

4. If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from May to August 2021 for Wet Age Related Macular Degeneration (wAMD) ONLY

- a. Aflibercept
- b. Bevacizumab
- c. Brolucizumab
- d. Dexamethasone
- e. Ranibizumab

Trust response:

Please note: The way the Pharmacy data is recorded has changed. Data is now collected by finance quarter:

Q1 April, May, June

Q2 July, August, September

Q3 October, November, December

Q4 January, February, March

The following data is for April 2021 to September 2021

1.

Row Labels	Q1	Q2	Grand Total
Aflibercept	1058	1142	2200
bevacizumab	50	61	111
dexamethasone (ozurdex)	100	72	172
fluocinolone acetonide	5	3	8
Ranibizumab	458	486	944
(blank)			
<b>Grand Total</b>	<b>1671</b>	<b>1764</b>	<b>3435</b>

2. This information is not stored in pharmacy and would require the manual checking of patient records. The Trust is applying exemption S12 to this question.

3.

	Drug Conversion	Q1	Q2	Grand Total
1	Aflibercept	1803	2052	3855
	bevacizumab	67	83	150
	dexamethasone (ozurdex)	113	87	200
	fluocinolone acetonide	6	5	11
	Ranibizumab	835	869	1704
		<b>2824</b>	<b>3096</b>	<b>5920</b>

4.

	Q1	Q2
Aflibercept Age-related macular degeneration (disorder) (wet)	605	721
Ozurdex Age-related macular degeneration (disorder) (wet)	4	0
Ranibizumab Age-related macular degeneration (disorder) (wet)	281	279